This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medicines Company Posts Full Inclisiran Data From ASCVD Study
by Zacks Equity Research
The Medicines Company (MDCO) reports detailed data from the phase III ORION-10 study on its lead candidate inclisiran to treat patients with ASCVD.
VistaGen's (VTGN) Major Depressive Disorder Drug Disappoints
by Zacks Equity Research
VistaGen (VTGN) announces disappointing results from the ELEVATE study on MDD candidate, AV-101.
Amarin (AMRN) Gets FDA Panel Nod for Vascepa Label Expansion
by Zacks Equity Research
Amarin (AMRN) gets favorable FDA Advisory Committee vote to expand the label of Vascepa capsules to reduce cardiovascular risk in patients with persistent elevated triglycerides.
Sarepta (SRPT) Stock Down Despite New $48M Gene Therapy Deal
by Zacks Equity Research
Sarepta (SRPT) expands its footing in the gene therapy field and signs a deal with StrideBio to develop up to eight new treatments.
BioDelivery (BDSI) Stock Up on Q3 Earnings Beat & Raised View
by Madhu Goel
BioDelivery (BDSI) beats earnings and sales expectations in the third quarter of 2019. The company raises its 2019 revenue guidance.
QIAGEN (QGEN) Catches Eye: Stock Jumps 9.9%
by Zacks Equity Research
QIAGEN (QGEN) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Halozyme Therapeutics (HALO) Looks Good: Stock Adds 5.4% in Session
by Zacks Equity Research
Halozyme Therapeutics (HALO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Catalyst's (CPRX) Q3 Earnings Beat Estimates, Sales Miss
by Zacks Equity Research
Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2019.
IVERIC bio (ISEE) Q3 Loss Narrows Y/Y, Zimura Advancing Well
by Zacks Equity Research
IVERIC bio's (ISEE) third-quarter earnings improve year over year. The company plans to initiate a pivotal study on Zimura for treating GA early next year.
Amicus' (FOLD) Shares Rise on Q3 Earnings & Revenue Beat
by Zacks Equity Research
Amicus (FOLD) reports a narrower-than-expected loss and beats sales estimates in the third quarter of 2019.
Spectrum Pharma's (SPPI) Q3 Loss Narrows, Focus on Rolontis
by Zacks Equity Research
Spectrum Pharma (SPPI) posts a narrower-than-expected loss for the third quarter of 2019.
PDL BioPharma (PDLI) Q3 Earnings Beat, LENSAR Drives Sales
by Zacks Equity Research
PDL BioPharma (PDLI) impresses investors with third-quarter earnings beat. LENSAR laser system bumps up sales as well. However, revenues fall year over year.
Emergent (EBS) Beat Earnings in Q3, Vaccines Drive Sales
by Zacks Equity Research
Emergent (EBS) rides high on both earnings and revenues beat in the third quarter. ACAM2000 and Narcan drive revenues.
Blueprint Medicines (BPMC) Q3 Earnings & Sales Top Estimates
by Zacks Equity Research
Blueprint Medicines' (BPMC) loss is narrower than estimated in the third quarter with revenues also beating the mark. Shares rise.
Acorda (ACOR) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Acorda (ACOR) posts narrower-than-expected loss with revenues also topping estimates in the third quarter. Inbrija is also off to a promising start with sales rising sequentially.
AMAG Q3 Loss Wider Than Expected, Revenues Lag Estimates
by Zacks Equity Research
AMAG disappoints investors with earnings and sales miss in the third quarter.
The Zacks Analyst Blog Highlights: Unifi, BioDelivery Sciences International, Crocs, Anika Therapeutics and Plexus
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Unifi, BioDelivery Sciences International, Crocs, Anika Therapeutics and Plexus
Repligen (RGEN) Beats on Q3 Earnings, Lifts 2019 Guidance
by Zacks Equity Research
Repligen (RGEN) rides high on earnings and revenue beat in the third quarter of 2019. The company also raises 2019 guidance.
5 Top Momentum Stocks in October That Still Have Upside Left
by Nalak Das
Possibility of at least an interim trade deal between the largest trading countries of the world boosted investors' confidence on risky assets like equities.
Immunomedics (IMMU) Reports Wider-Than-Expected Loss in Q3
by Zacks Equity Research
Immunomedics' (IMMU) loss lags estimates in Q3. The company fails to generate any revenues at the same time.
Vertex (VRTX) Q3 Earnings Beat, Revenues Lag Estimates
by Zacks Equity Research
Vertex (VRTX) encourages investors with better-than-expected earnings in Q3. However, the top line misses the mark.
What Makes Anika Therapeutics (ANIK) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Anika Therapeutics (ANIK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Anika Therapeutics, Inc. (ANIK) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Anika Therapeutics, Inc. (ANIK).
Anika Therapeutics (ANIK) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Anika (ANIK) delivered earnings and revenue surprises of 56.10% and 9.61%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include: KB Home, Crocs, NetEase, Taylor Morrison Home and Anika Therapeutics
by Zacks Equity Research
Zacks.com featured highlights include: KB Home, Crocs, NetEase, Taylor Morrison Home and Anika Therapeutics